{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:33:25Z","timestamp":1791228805633,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T00:00:00Z","timestamp":1407974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s10549-014-3091-7","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T10:11:15Z","timestamp":1407924675000},"page":"237-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review"],"prefix":"10.1007","volume":"147","author":[{"given":"S. J.","family":"Ioannides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. L.","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Elwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,14]]},"reference":[{"key":"3091_CR1","volume-title":"Obesity: epidemiology, pathophysiology, and prevention","author":"D Bagchi","year":"2013","unstructured":"Bagchi D, Preuss H (2013) Obesity: epidemiology, pathophysiology, and prevention, vol 2nd. CRC Press, New York"},{"key":"3091_CR2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10549-012-2073-x","volume":"134","author":"S Niraula","year":"2012","unstructured":"Niraula S, Ocana A, Ennis M et al (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 134:769\u2013781","journal-title":"Breast Cancer Res Treat"},{"key":"3091_CR3","unstructured":"National Health Institute. Obesity and cancer risk. secondary obesity and cancer risk. http:\/\/www.cancer.gov\/cancertopics\/factsheet\/Risk\/obesity . Accessed 18 July 2014"},{"key":"3091_CR4","unstructured":"GLOBOCAN (2012) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Secondary GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx . Accessed 18 July 2014"},{"issue":"9","key":"3091_CR5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/00003495-200868090-00007","volume":"68","author":"M Sanford","year":"2008","unstructured":"Sanford M, Plosker GL (2008) Anastrozole. Drugs 68(9):1319\u20131340. doi: 10.2165\/00003495-200868090-00007","journal-title":"Anastrozole. Drugs"},{"issue":"24","key":"3091_CR6","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"348","author":"IE Smith","year":"2003","unstructured":"Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431\u20132442","journal-title":"N Engl J Med"},{"issue":"7","key":"3091_CR7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1940-6207.CAPR-11-0110","volume":"4","author":"PG Morris","year":"2011","unstructured":"Morris PG, Hudis CA, Giri D et al (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 4(7):1021\u20131029","journal-title":"Cancer Prev Res"},{"issue":"3","key":"3091_CR8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/1940-6207.CAPR-10-0381","volume":"4","author":"K Subbaramaiah","year":"2011","unstructured":"Subbaramaiah K, Howe LR, Bhardwaj P et al (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 4(3):329\u2013346","journal-title":"Cancer Prev Res"},{"issue":"21","key":"3091_CR9","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1200\/JCO.2010.29.5113","volume":"28","author":"PJ Goodwin","year":"2010","unstructured":"Goodwin PJ, Pritchard KI (2010) Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol 28(21):3405\u20133407","journal-title":"J Clin Oncol"},{"issue":"3","key":"3091_CR10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10549-011-1874-7","volume":"131","author":"R Wolters","year":"2012","unstructured":"Wolters R, Schwentner L, Regierer A et al (2012) Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat 131(3):925\u2013931","journal-title":"Breast Cancer Res Treat"},{"key":"3091_CR11","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, et al, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7): e1000097. doi: 10.1371\/journal.pmed.1000097","DOI":"10.1371\/journal.pmed.1000097"},{"issue":"32","key":"3091_CR12","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","volume":"30","author":"M Ewertz","year":"2012","unstructured":"Ewertz M, Gray KP, Regan MM et al (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30(32):3967\u20133975","journal-title":"J Clin Oncol"},{"issue":"3","key":"3091_CR13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/bjc.2013.367","volume":"109","author":"M Gnant","year":"2013","unstructured":"Gnant M, Pfeiler G, Stoger H et al (2013) The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer 109(3):589\u2013596","journal-title":"Br J Cancer"},{"issue":"11","key":"3091_CR14","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/bjc.2012.473","volume":"107","author":"MAN Sendur","year":"2012","unstructured":"Sendur MAN, Aksoy S, Zengin N et al (2012) Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. Br J Cancer 107(11):1815\u20131819","journal-title":"Br J Cancer"},{"issue":"21","key":"3091_CR15","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","volume":"28","author":"I Sestak","year":"2010","unstructured":"Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411\u20133415","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"3091_CR16","doi-asserted-by":"crossref","first-page":"e11020","DOI":"10.1200\/jco.2012.30.15_suppl.e11020","volume":"30","author":"U Sahin","year":"2012","unstructured":"Sahin U, Petekkaya I, Arslan C et al (2012) Impact of obesity in postmenopausal early breast cancer patients receiving frontline adjuvant aromatase inhibitors. J Clin Oncol 30(suppl):e11020","journal-title":"J Clin Oncol"},{"key":"3091_CR17","first-page":"55a","volume":"21","author":"LB Michaud","year":"2002","unstructured":"Michaud LB, Buzdar AU, Rubin S et al (2002) The efficacy of anastrozole is not dependent upon body mass index (BMI) in postmenopausal women with advanced breast cancer (BC). Proc Am Soc Clin Oncol 21:55a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"3091_CR18","first-page":"103a","volume":"19","author":"P Schmid","year":"2000","unstructured":"Schmid P, Possinger K, Bohm R et al (2000) Body mass index as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or Megestrol Acetate. Proc Am Soc Clin Oncol 19:103a","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"4","key":"3091_CR19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00002018-199921040-00005","volume":"27","author":"LB Michaud","year":"1999","unstructured":"Michaud LB, Buzdar AU (1999) Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 27(4):297\u2013309","journal-title":"Drug Saf"},{"key":"3091_CR20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1470-2045(11)70046-8","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Sestak I, Baum M et al (2011) 10-year analysis of the ATAC trial: wrong conclusion?\u2014Authors\u2019 reply. lancet 12:201\u2013312","journal-title":"lancet"},{"key":"3091_CR21","doi-asserted-by":"crossref","first-page":"11845","DOI":"10.1093\/jnci\/djm246","volume":"99","author":"R Jakesz","year":"2007","unstructured":"Jakesz R, Greil R, Gnant M (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast and colorectal cancer study group trial 6a. J Natl Cancer Inst 99:11845\u201311853","journal-title":"J Natl Cancer Inst"},{"key":"3091_CR22","doi-asserted-by":"crossref","unstructured":"Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8\u00b71\u00a0years median follow-up. Lancet Oncol 12(12):1101\u20131108. http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clcentral\/articles\/418\/CN-00804418\/frame.html . Accessed 18 July 2014","DOI":"10.1016\/S1470-2045(11)70270-4"},{"key":"3091_CR23","doi-asserted-by":"crossref","unstructured":"Goss PE (2006) Preventing relapse beyond 5\u00a0years: the MA.17 extended adjuvant trial. Semin Oncol 33(2 Suppl 7):S8\u201312 doi: 10.1053\/j.seminoncol.2006.03.025","DOI":"10.1053\/j.seminoncol.2006.03.025"},{"issue":"12","key":"3091_CR24","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","volume":"26","author":"EP Mamounas","year":"2008","unstructured":"Mamounas EP, Jeong JH, Wickerham DL et al (2008) Benefit from exemestane as extended adjuvant therapy after 5\u00a0years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 26(12):1965\u20131971. doi: 10.1200\/jco.2007.14.0228","journal-title":"J Clin Oncol"},{"issue":"19","key":"3091_CR25","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","volume":"29","author":"G Pfeiler","year":"2011","unstructured":"Pfeiler G, Konigsberg R, Fesl C et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653\u20132659","journal-title":"J Clin Oncol"},{"issue":"24","key":"3091_CR26","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2012.42.0273","volume":"30","author":"E Folkerd","year":"2012","unstructured":"Folkerd E, Dixon J, Renshaw L et al (2012) Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 30(24):2977\u20132980","journal-title":"J Clin Oncol"},{"key":"3091_CR27","first-page":"209","volume":"5","author":"M Kittaneh","year":"2011","unstructured":"Kittaneh M, Gluck S (2011) Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer 5:209\u2013226. doi: 10.4137\/BCBCR.S6234","journal-title":"Breast Cancer"},{"issue":"3","key":"3091_CR28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.20.3.751","volume":"20","author":"J Geisler","year":"2002","unstructured":"Geisler J, Haynes B, Anker G et al (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20(3):751\u2013757","journal-title":"J Clin Oncol"},{"key":"3091_CR29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1023\/A:1008226721932","volume":"9","author":"M Gershanovich","year":"1998","unstructured":"Gershanovich M, Chaudri HA, Campos D et al (1998) Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5\u00a0mg daily, 0.5\u00a0mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9:639\u2013645","journal-title":"Ann Oncol"},{"issue":"7","key":"3091_CR30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","volume":"12","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7):631\u2013641","journal-title":"Lancet Oncol"},{"issue":"1\u20135","key":"3091_CR31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0960-0760(01)00050-4","volume":"76","author":"AS Bhatnagar","year":"2001","unstructured":"Bhatnagar AS, Brodie AMH, Long BJ et al (2001) Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem and Mol Biol 76(1\u20135):199\u2013202. doi: 10.1016\/S0960-0760(01)00050-4","journal-title":"J Steroid Biochem and Mol Biol"},{"key":"3091_CR32","doi-asserted-by":"crossref","unstructured":"Miller W (2008) Background and development of aromatase inhibitors. In: BJA F (ed) Milestones in drug therapy, aromatase inhibitiors, 2nd edn. pp 1\u201321","DOI":"10.1007\/978-3-7643-8693-1_1"},{"issue":"1","key":"3091_CR33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00682742","volume":"30","author":"M Dowsett","year":"1994","unstructured":"Dowsett M, Coombes RC (1994) Second generation aromatase inhibitor\u20144-hydroxyandrostenedione. Breast Cancer Res Treat 30(1):81\u201387. doi: 10.1007\/BF00682742","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"3091_CR34","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.2007.13.9279","volume":"26","author":"JM Dixon","year":"2008","unstructured":"Dixon JM, Renshaw L, Young O et al (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26(10):1671\u20131676. doi: 10.1200\/JCO.2007.13.9279","journal-title":"J Clin Oncol"},{"issue":"16","key":"3091_CR35","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/S0959-8049(03)00630-0","volume":"39","author":"C Rose","year":"2003","unstructured":"Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39(16):2318\u20132327","journal-title":"Eur J Cancer"},{"key":"3091_CR36","unstructured":"World Health Organization. BMI classification. Secondary BMI classification. http:\/\/apps.who.int\/bmi\/index.jsp?introPage=intro_3.html . Accessed 18 July 2014"},{"issue":"3","key":"3091_CR37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0959-8049(95)00014-3","volume":"32A","author":"W Jonat","year":"1996","unstructured":"Jonat W, Howell A, Blomqvist C et al (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A(3):404\u2013412","journal-title":"Eur J Cancer"},{"key":"3091_CR38","doi-asserted-by":"crossref","unstructured":"Buzdar AU, Jones SE, Vogel CL et al (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. The Arimidex Study Group. Cancer 79:730\u2013739. http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clcentral\/articles\/225\/CN-00204225\/frame.html . Accessed 18 July 2014","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO;2-0"},{"issue":"Suppl 6","key":"3091_CR39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12325-011-0033-1","volume":"28","author":"AF Ortega","year":"2011","unstructured":"Ortega AF, Lopez LJ, Villaro GV et al (2011) Individualization of treatment strategies. Adv Ther 28(Suppl 6):19\u201338","journal-title":"Adv Ther"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3091-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-3091-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3091-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T01:16:48Z","timestamp":1598145408000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-3091-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,14]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["3091"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-3091-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,14]]}}}